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Purpose: To report the efficacy of grid photocoagulation combined with intravitreal 
  bevacizumab (IVB) for macular edema recurring after previous IVBs associated with retinal 
vein occlusion (RVO).
Methods: This retrospective study consisted of 19 eyes with branch retinal vein occlusion 
(BRVO) and nine eyes with central retinal vein occlusion (CRVO), which were treated with 
grid photocoagulation combined with IVB for recurrent macular edema after previous IVBs. 
The mean duration of total follow-up was 29.3 ± 5.8 months.
Results: After this combination therapy, foveal thickness was reduced, significant with slight 
improvement in visual acuity (VA). At 1 month after treatment, although 25 of the 28 eyes showed 
complete resolution of the cystoid space, the macular edema recurred to some extent in 19 eyes. 
Compared with initial values, final foveal thickness was reduced significantly in both BRVO and 
CRVO groups (P , 0.001), but improvement in VA was significant only for eyes with BRVO 
(P = 0.012). The total number of IVB was 2.8 ± 0.7 for eyes with either BRVO or CRVO.
Conclusion: Grid photocoagulation combined with IVB has a substantial effect on reducing 
recurrent macular edema associated with RVO, but the effect on visual acuity is limited.
Keywords: bevacizumab, grid laser photocoagulation, macular edema, optical coherence 
tomography, retinal vein occlusion
Introduction
Macular edema remains one of the most common vision-threatening complications 
associated with retinal vascular disease such as retinal vein occlusion (RVO) or dia-
betic retinopathy,1–4 although various treatments have been reported to reduce this 
macular edema.5–11 Dysfunction of the endothelial blood–retinal barrier and increased 
vascular permeability may lead to leakage from the retinal capillaries, which results 
in macular edema. Today, vascular endothelial growth factor (VEGF) is known to 
play a major role in this increased vascular permeability.12 Because of the promising 
short-term effects of intravitreal bevacizumab (IVB),13 which is a recombinant human 
monoclonal antibody that binds to VEGF, anti-VEGF therapy is becoming a primary 
treatment for this condition.14 The effect of anti-VEGF agents is rapid, albeit short,15 
and we often see a recurrence of the macular edema after complete resolution brought 
about by the IVB. Consequently, repeated IVB tends to usually be necessary.16
Grid photocoagulation is an evidence-based treatment of the macular edema 
associated with RVO. In a report by the Branch Vein Occlusion Study Group,10 grid 
photocoagulation to macular edema caused by branch retinal vein occlusion (BRVO) 
significantly improved long-term visual prognosis. In central retinal vein occlusion Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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(CRVO), however, grid photocoagulation reduced the 
angiographic evidence of macular edema, but did not lead 
to improvement in the vision of treated eyes.1 Based on 
these reports, grid photocoagulation does have long-term 
effects on the reduction of macular edema due to RVO, but 
it is sometimes difficult to perform effective coagulation in 
eyes that have severe macular edema and retinal detachment 
due to acute RVO. The rapid effect of IVB in reducing the 
macular thickening may allow clinicians to perform grid 
photocoagulation more effectively and safely. In the study 
described herein, we report both the safety and efficacy of 
grid photocoagulation in combination with IVB for recurrent 
macular edema associated with RVO.
Patients and methods
For this retrospective study, we reviewed the medical 
records of 28 patients (28 eyes) who underwent grid 
photocoagulation combined with IVB for macular edema 
associated with RVO that recurred after the previous IVBs. 
In the present study, 19 patients (19 eyes) with BRVO 
and nine patients (nine eyes) with CRVO were examined 
at Kyoto University   Hospital between December 2007 
and November 2008. At the time of initial IVB (Avastin; 
  Genentech, San Francisco, CA), all eyes showed macular 
edema with a loss of vision. Each patient underwent one 
or two injections of IVB for their macular edema. After 
the initial treatment with IVB, however, all eyes showed a 
recurrence. As treatment for the recurrent macular edema, 
each patient underwent an additional IVB first. Grid photo-
coagulation was performed immediately after the macular 
edema had been reduced by IVB.
Eyes with co-existing ocular disease (ie, epiretinal 
membrane, glaucoma, or proliferative diabetic retinopathy) 
were not recruited for this study. Pseudophakic eyes were 
included, but eyes that had undergone a prior vitrectomy 
were excluded. In the 28 eyes included in this study, 
previous treatment for macular edema before the initial IVB 
included three eyes that had been treated with grid laser 
photocoagulation, five eyes that had received intravitreal or 
posterior sub-Tenon injections of triamcinolone acetonide, 
and 1 eye that had received intravitreal injections of tissue 
plasminogen activator. All patients had at least a 12-month 
follow-up after the combination therapy; the mean duration 
of total follow-up time was 29.3 ± 5.8 months. This study was 
approved by the Institutional Ethics Committee and adhered 
to the tenets of the Declaration of Helsinki. Written informed 
consent was obtained from each patient.
Patients who had a visual disturbance due to macular 
edema associated with RVO were initially offered IVB 
treatment. At the time of initial IVB, foveal thickness was 
greater than 300 µm and visual acuity (VA) was #0.7 
on a Landolt chart. Dosage of the bevacizumab was 
1.25 mg/0.05 mL per injection, and all injections were 
performed in the usual sterile fashion; prophylactic topical 
antibiotics were applied for 1 week after the injection.
Initially, 22 eyes underwent one IVB injection, and six 
eyes underwent two IVB injections. All patients in the current 
study showed macular edema recurring after the initial IVBs. 
A recurrence of macular edema was defined as a relapse of 
the cystoid space at the foveal center and an increase of the 
foveal thickness to .250 µm. For the recurrent macular 
edema, grid photocoagulation was performed immediately 
after the macular edema had been reduced by an additional 
IVB. Grid photocoagulation to the leaking area seen on the 
fluorescein angiogram was performed with a multicolor diode 
laser (MC-300; Nidek, Gamagori, Japan) with settings of 
561 nm wavelength and 100 µm spot size for 0.1 second; 
sufficient power (median 100 mW, range 70–140 mW) was 
used to produce a burn detectable at the level of the retinal 
pigment epithelium. Each patient was scheduled to visit our 
clinic for an examination every month after treatment.
All patients had undergone a comprehensive ophthalmo-
logic examination at each visit. This included best-corrected 
VA measurement, intraocular pressure determination, indirect 
ophthalmoscopy, slit-lamp biomicroscopy with a contact lens, 
and optical coherence tomography (OCT) examination. At 
the initial visit of each patient, fluorescein angiography was 
performed with a confocal laser scanning system (HRA-2; 
Heidelberg Engineering, Heidelberg, Germany); additional 
angiography was performed, if necessary. In the study 
described herein, macular area was examined precisely by 
OCT (Stratus OCT, Carl Zeiss, Dublin, CA; 3D-OCT1000, 
Topcon, Tokyo, Japan; Cirrus OCT, Carl Zeiss; RS3000; 
Nidek). Foveal thickness was calculated as the average retinal 
thickness within a circle having a 500-µm radius; the circle 
was centered on the fovea.
Statistical analysis was performed using PASW statistics, 
(v 17.0; SPSS, Chicago, IL). All values are presented as 
mean ± standard deviation. Best-corrected VA was measured 
with a Landolt chart and converted to a logarithm of the 
minimum angle of resolution (logMAR). VA and foveal 
thickness were compared with Tukey’s HSD test after one 
factor repeated measurement of analysis of variance. A P value 
of ,0.05 was considered to be statistically significant.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Results
Table 1 shows characteristics of the patients included in this 
study. Before initial IVBs, all eyes showed marked macular 
edema associated with RVO, often with a foveal cystoid 
space. Immediately after treatment, a reduction in clinical 
macular edema was seen and confirmed by OCT. Compared 
with preinjection measurements (656.5 ± 179.1 µm in 
the BRVO group and 780.8 ± 148.5 µm in the CRVO 
group), foveal thickness was decreased significantly to 
224.1 ± 102.2 µm in eyes with BRVO (P , 0.001) and to 
245.9 ± 101.2 µm in eyes with CRVO (P , 0.001) (Figure 1). 
In parallel with the reduction in macular edema, mean VA 
improved from 0.66 ± 0.35 to 0.37 ± 0.30 for eyes with BRVO 
(P , 0.001), and from 0.91 ± 0.38 to 0.69 ± 0.26 for eyes 
with CRVO (P = 0.067) (Figure 2). All eyes in the current 
study, however, had a recurrence of macular edema with a 
visual disturbance.
Just before the combination therapy (termed “baseline”), 
all eyes showed cystoid spaces beneath the fovea, and the 
mean thickness of the fovea had increased to 518 ± 112 µm 
in the BRVO group and to 589 ± 118 µm in the CRVO 
group. The elapsed times from the previous IVB to the 
current combined therapy was 8.1 ± 3.9 months for eyes 
with BRVO and 4.4 ± 1.5 months for eyes with CRVO. 
The improvement in VA brought about by the previous IVBs 
had partially receded at the baseline visit; mean VA was now 
0.53 ± 0.34 in the BRVO group and 0.81 ± 0.29 in the CRVO 
group. On the combination therapy, each eye underwent an 
IVB first. Grid photocoagulation was performed after the 
macular edema had cleared, at 11 ± 16 days after IVB in 
eyes with BRVO and at 15 ± 29 days after IVB in eyes with 
CRVO. With this combination therapy, foveal thickness was 
reduced significantly to 276.7 ± 90.9 µm in eyes with BRVO 
(P , 0.001) and to 246.3 ± 62.0 µm in eyes with CRVO 
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Figure 1 Mean foveal thickness in eyes that were treated with grid photocoagulation 
combined with an intravitreal bevacizumab (iVB) for the treatment of recurrent 
macular edema associated with retinal vein occlusion. 
Notes: * P  ,  0.05  and  †P  ,  0.01,  compared  with  values  before  the  initial 
treatment; ‡P , 0.05 and #P , 0.01, compared with baseline values (just before grid 
photocoagulation combined with iVB).
Abbreviation: M, month(s).
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Figure  2  Visual  acuity  in  logMAr  of  eyes  treated  with  grid  photocoagulation 
combined with an intravitreal bevacizumab (iVB) for the treatment of recurrent 
macular edema associated with retinal vein occlusion. 
Notes: *P , 0.05 and †P , 0.01, compared with values before the initial treatment; 
‡P  ,  0.05,  compared  with  baseline  values  (just  before  grid  photocoagulation 
combined with iVB).
Abbreviation: M, month(s).
Table 1 Background of the subjects
BRVO CRVO
number of eyes 19 9
gender (male/female) 5/14 7/2
Age (years) 72.4 ± 7.7 74.1 ± 8.2
hypertension 6 7
Diabetes 4 1
Fluorescein angiography  
(ischemic/nonischemic)
11/8 0/9
Before initial iVB
  Visual acuity (logMAr) 0.66 ± 0.35 0.91 ± 0.38
  Foveal thickness (µm) 656.5 ± 179.1 780.8 ± 148.5
  number of iVB (once/twice) 13/6 9/0
Baseline
  Visual acuity (logMAr) 0.53 ± 0.34 0.81 ± 0.29
  Foveal thickness (µm) 518.4 ± 112.5 588.6 ± 118.4
Duration between initial iVB  
and baseline (months)
8.1 ± 3.9 4.4 ± 1.5
Follow-up (months) 22.0 ± 6.1 23.3 ± 4.8
Abbreviations: BrVO, branch retinal vein occlusion; CrVO, central retinal vein 
occlusion; iVB, intravitreal injection of bevacizumab; ischemic BrVO, showing .5 
disc diameters of nonperfusion area; ischemic CrVO, showing .10 disc areas of 
nonperfusion; logMAr, logarithm of the minimum angle of resolution.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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(P , 0.001) at 1 month after treatment, and VA improved 
slightly to 0.43 ± 0.30 in eyes with BRVO (P = 0.534), and to 
0.72 ± 0.30 in eyes with CRVO (P = 0.928). Also at 1 month 
after treatment, 17 of the 19 eyes with BRVO and eight of 
the nine eyes with CRVO showed complete resolution of the 
cystoid space (Figure 3). Thereafter, however, the cystoid 
space reappeared, to at least some extent, in twelve eyes 
with BRVO and in seven eyes with CRVO (Figure 4). Mean 
duration from the combination therapy to the recurrence was 
3.3 ± 1.2 months in eyes with BRVO and 3.4 ± 0.8 months 
in eyes with CRVO. Ten eyes with BRVO and three eyes 
with CRVO needed additional IVB or grid photocoagulation, 
so the total number of IVBs was 2.8 ± 0.7 for both BRVO 
and CRVO.
Mean follow-up after this therapy was 22.0 ± 6.1 months 
in BRVO eyes and 23.3 ± 4.8 months in eyes with CRVO. 
At the final visit, macular edema had resolved completely 
and there was no cystoid space in 14 eyes with BRVO and 
in six eyes with CRVO. Figures 1 and 2 indicate the changes 
in foveal thickness and in VA with the series of treatments. 
At the final visit, foveal thickness was still significantly 
reduced compared with that at baseline in eyes with BRVO 
(P , 0.001) and in eyes with CRVO (P , 0.001).   However, 
improvement in VA had receded at the final visit and returned 
to the baseline values (0.47 ± 0.34 [P = 0.974] in BRVO 
eyes, 0.85 ± 0.50 [P = 0.999] in CRVO eyes). Comparing 
both VA and foveal thickness just before the initial IVB, 
final foveal thickness was reduced significantly in both 
BRVO eyes and CRVO eyes (P , 0.001, respectively), but 
the improvement in VA was significant only in those eyes 
with BRVO (P = 0.012).
Discussion
An increasing number of reports show the efficacy of anti-
VEGF therapy for macular edema secondary to RVO. Today, 
IVB is used to treat macular edema primarily in an off-label 
manner, as it was approved originally for the treatment of 
colon cancer. While the effect of IVB is rapid, it is usually 
necessary for repeated injections to maintain the initial effect. 
In a collaborative retina study, the mean number of 1.25 mg 
IVB injections over a 24-month period was 7.2 for the treat-
ment of macular edema associated with CRVO.17 Recently, 
Figure 3 no recurrence of macular edema after grid photocoagulation combined 
with intravitreal bevacizumab (iVB) for recurrent macular edema associated with 
branch retinal vein occlusion. (A) An 83-year-old woman had a visual disturbance 
in the left eye (0.3 Os) due to macular edema associated with branch retinal vein 
occlusion. (B) Fluorescein angiogram shows fluorescein leakage from the capillaries. 
(C–G), Vertical sectional images centered on the fovea with optical coherence 
tomography were obtained at the initial visit (C), at 1 month after the initial iVB 
(D), just before the combined therapy (at baseline, E), at 1 month after combined 
therapy (F), and at the final visit (G). she had no recurrence after the combination 
therapy (0.8 Os).
Figure 4 recurrence of macular edema after grid photocoagulation combined with 
intravitreal bevacizumab (iVB) for recurrent macular edema associated with branch 
retinal vein occlusion. (A) A 65-year old woman had a visual disturbance in the right 
eye (0.6 OD) due to macular edema associated with branch retinal vein occlusion. 
(B) Fluorescein angiogram shows fluorescein leakage from the capillaries. (C–G), 
Vertical sectional images centered on the fovea with optical coherence tomography 
were obtained at the initial visit (C), at 1 month after initial iVB (D), just before 
the combined therapy (at baseline, E), at 1 month (F) and at 3 months (G) after 
the combined therapy. she had a recurrent cystoid space beneath the fovea after 
combination therapy (0.9 OD).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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however, large randomized clinical trials have revealed the 
6-month results of monthly injections of ranibizumab for 
RVO. 18,19 With monthly injections over 6 months, retinal 
thickening was continuously resolved and .40% of eyes 
with CRVO and .50% of eyes with BRVO gained 15 letters 
on VA testing, and a VA of $20/40 was achieved in 40% 
of eyes with CRVO and in 60% of eyes with BRVO. Based 
on these reports, frequent injection of this anti-VEGF agent 
seems to be promising for macular edema due to RVO. Once 
the treatment has stopped, however, recurrence may occur. 
In addition, repeated intravitreal injections of any anti-VEGF 
agent increase the systemic and ocular adverse effects.
To reduce the number of injections, it would be 
effective (1) to distinguish those patients who do not require 
retreatment,20,21 (2) to design the optimum dosing and 
sequence,14,17,22,23 or (3) to switch to some other treatment if 
anti-VEGF therapy is not effective. In the current study, we 
aimed to reduce the number of IVB in eyes with recurrent 
macular edema by co-performing grid photocoagulation. 
Since the Branch Vein Occlusion Study Group recommended 
grid photocoagulation for macular edema associated with 
BRVO, for 25 years this has been seen as the primary 
treatment. The Central Vein Occlusion Study Group 
reported that grid photocoagulation reduced angiographic 
macular edema in eyes with CRVO.7 However, it may be 
difficult to perform effective coagulation when macular 
edema and retinal detachment are severe. In such cases, it 
is often necessary to increase the laser power in order to 
ensure sufficient coagulation, and it may be necessary to 
frequently change the laser intensity depending on the extent 
of retinal thickening and hemorrhage. By combining IVB 
with photocoagulation, we were able to produce burns with 
a relatively low setting of the laser (100 mW in intensity, 
0.1 millisecond in duration, 100 µm in spot size). This 
protocol allowed us to perform grid photocoagulation more 
safely;24 so far, no adverse effects have been detected in these 
patients, except for the recurrence of the macular edema.
In this study, the combination therapy was performed to 
macular edema recurred after the effective previous IVB. 
This combination treatment reduced foveal thickness as 
effectively as did the previous IVB. However, improvement 
in VA was not as effective as was the previous IVB. Cystoid 
edema had resolved completely in 89% of eyes at 1 month, 
but 63%–78% of eyes ultimately showed a recurrence. At 
the final visit, although foveal thickness was significantly 
reduced compared with baseline values, improvement in VA 
had receded and had returned to baseline values. Compared 
with measurements just before the initial IVB, final foveal 
thickness was reduced significantly in both the BRVO and 
CRVO groups, but the improvement in VA was significant 
only in eyes with BRVO. Based on the current findings, grid 
photocoagulation has the substantial effect of reducing the 
macular edema associated with RVO, but its efficacy for 
visual recovery appears to be limited.
Limitations of the current study are the retrospective 
nature and small sample size. Our study lacked control 
arms: patients who were continued on IVB alone when 
their macular edema recurred, and those who received 
continuous monthly IVB throughout the study period. In 
addition, this study consisted of only those patients with 
recurrent macular edema, so that it is difficult to compare 
our current results with those of other reports. Based on 
the current results, however, the effect of this combination 
therapy on visual recovery is limited. Because the total 
number of injections of IVB was 2.8 ± 0.7 for both the 
BRVO and CRVO groups during a mean total follow-up 
period of 29.3 ± 5.8 months, the number of IVB injections 
is low. In addition, grid   photocoagulation in our study was 
performed quite safely and with low laser intensity. Based 
on the current results, we suggest that grid photocoagula-
tion combined with IVB be used for recurrent macular 
edema associated with RVO – at least when it is difficult 
to perform repeated IVB.
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